Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

BACKGROUND: In the phase 2 CAMMS223 trial (NCT00050778), alemtuzumab significantly improved clinical and MRI outcomes versus subcutaneous interferon beta-1a over 3 years in treatment-naive patients with relapsing–remitting MS. Here, we assess efficacy and safety of alemtuzumab over 12 years in CAMMS...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Neurol
Autors principals: Steingo, Brian, Al Malik, Yaser, Bass, Ann D., Berkovich, Regina, Carraro, Matthew, Fernández, Óscar, Ionete, Carolina, Massacesi, Luca, Meuth, Sven G., Mitsikostas, Dimos D., Pardo, Gabriel, Simm, Renata Faria, Traboulsee, Anthony, Choudhry, Zia, Daizadeh, Nadia, Compston, D. Alastair S.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2020
Matèries:
Original Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7578137/
https://ncbi.nlm.nih.gov/pubmed/32583052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-020-09983-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars